Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

(2010) Shelly S. Lo et al.   JOURNAL OF CLINICAL ONCOLOGY

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

The influence of a Gene expression profile on breast cancer decisions

(2009) Leonard R. Henry et al.   JOURNAL OF SURGICAL ONCOLOGY

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

(2008) Juhi Asad et al.   AMERICAN JOURNAL OF SURGERY

A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer

(2008) X.-J. Ma et al.   CLINICAL CANCER RESEARCH

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

(2008) Lori J. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

(2008) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathologic variables predict Oncotype DX™ Recurrence Score

(2008) Melina B Flanagan et al.   MODERN PATHOLOGY

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients

(2007) Ido Wolf et al.   CANCER